Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$47.91 USD
-2.08 (-4.16%)
Updated May 14, 2024 04:00 PM ET
After-Market: $47.97 +0.06 (0.13%) 7:44 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Janux Therapeutics, Inc. (JANX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$70.00 | $100.00 | $50.00 | 40.03% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Janux Therapeutics, Inc. comes to $70.00. The forecasts range from a low of $50.00 to a high of $100.00. The average price target represents an increase of 40.03% from the last closing price of $49.99.
Analyst Price Targets (5 )
Broker Rating
Janux Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, seven are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/21/2024 | BTIG | Kaveri Pohlman | Not Available | Strong Buy |
3/20/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Not Available | Strong Buy |
3/11/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
3/11/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
2/27/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $70.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 92 of 252 |
Current Quarter EPS Est: | -0.31 |